Teriflunomide Safety and Efficacy in Advanced Progressive Multiple Sclerosis.
Vanessa F Moreira FerreiraDanielle CaeferNatalie Erlich-MalonaBrian C HealyTanuja ChitinisJames M StankiewiczPublished in: Multiple sclerosis international (2020)
In an advanced progressive multiple sclerosis population, no substantial differences in tolerability, safety, sustained EDSS progression, or sustained T25FW worsening over time were observed between glatiramer acetate and teriflunomide-treated groups. The small sample precluded definitive determination.